"Moderna agreed to pay up to $2.25 billion to resolve all worldwide litigation, including a $950 million upfront payment due in July 2026 and a $1.3 billion contingent payment tied to the outcome of a separate government contractor liability appeal. In exchange, Moderna receives a global non-exclusive license to use the LNP technology for infectious disease applications with no future royalties owed."
"That last part matters. Moderna's entire pipeline, from its flu vaccine to its cancer immunotherapy work with Merck, depends on mRNA delivery. Removing the royalty burden and resolving all related litigation gives the company a cleaner runway to commercialize its next wave of products without a legal sword hanging over every approval."
Moderna announced a settlement with Arbutus Biopharma and Genevant Sciences resolving a years-long patent dispute over lipid nanoparticle (LNP) delivery technology used in mRNA vaccines. The agreement requires Moderna to pay $2.25 billion total, including $950 million upfront in July 2026 and $1.3 billion contingent on a government contractor liability appeal outcome. In return, Moderna receives a global non-exclusive license to use LNP technology for infectious disease applications without future royalties. This resolution eliminates a significant legal overhang and provides clarity for Moderna's pipeline development, including flu vaccines and cancer immunotherapy collaborations. The stock has gained 69% year-to-date, and the settlement strengthens investor confidence in the company's commercialization prospects.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]